Royalty Pharma plc RPRX

Rank #678 · Nasdaq · $26.1B market cap

Audited by Ernst & Young LLP, no going-concern flag in the latest filing.

Score

60.4

P/E

23.0

P/B

2.74

ROE

11.9%

Op. Margin

63.4%

Debt Ratio

83%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★★☆☆

Good

P/E 23.0x, P/B 2.74x. Ranks in the top 40% of the universe.

Profitability ★★★★☆

Good

ROE 11.9%. Ranks in the top 21% of the universe.

Safety ★★★☆☆

Good

Debt ratio 83%. Ranks in the top 34% of the universe.

Growth ★★★☆☆

Average

Revenue growth of 5.2% year over year. Ranks in the top 48% of the universe.

Profitability is the relative strength · Valuation is the relative weakness (relative to this universe).

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2020	$1.8B	$1.4B	$1.4B	$4.5B	76.0	141
2021	$1.8B	$2.6B	$2.3B	$4.6B	144.6	135
2022	$2.1B	$1.6B	$1.0B	$6.1B	75.2	118
2023	$2.3B	$1.4B	$0.6B	$9.9B	62.5	74
2024	$2.2B	$0.3B	$0.0B	$10.2B	13.7	61
2025	$2.4B	$1.5B	$1.1B	$9.5B	63.4	83